Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update By: Theratechnologies via GlobeNewswire February 06, 2024 at 07:30 AM EST MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT. Theratechnologies will also provide further information on the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Company’s supplemental Biologics License Application for the F8 formulation of tesamorelin. The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc, Senior Vice President and Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks. Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below. CONFERENCE CALL INFORMATIONConference Call DateFebruary 21, 2024Conference Call Time8:30 a.m. EDTWebcast linkhttps://edge.media-server.com/mmc/p/6fyph854Dial in1-888-317-6003 (toll free) or 1-412-317-6061 (international)Access Code0664356CONFERENCE CALL REPLAYToll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)International Toll1-412-317-0088Replay Access Code3842515Replay End DateFebruary 28, 2024To access the replay using an international dial-in number, please select this link:https://services.choruscall.com/ccforms/replay.html An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter). Contacts: Philippe DubucSenior Vice President and Chief Financial Officerpdubuc@theratech.com438-315-6608 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update By: Theratechnologies via GlobeNewswire February 06, 2024 at 07:30 AM EST MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT. Theratechnologies will also provide further information on the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Company’s supplemental Biologics License Application for the F8 formulation of tesamorelin. The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc, Senior Vice President and Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks. Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below. CONFERENCE CALL INFORMATIONConference Call DateFebruary 21, 2024Conference Call Time8:30 a.m. EDTWebcast linkhttps://edge.media-server.com/mmc/p/6fyph854Dial in1-888-317-6003 (toll free) or 1-412-317-6061 (international)Access Code0664356CONFERENCE CALL REPLAYToll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)International Toll1-412-317-0088Replay Access Code3842515Replay End DateFebruary 28, 2024To access the replay using an international dial-in number, please select this link:https://services.choruscall.com/ccforms/replay.html An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter). Contacts: Philippe DubucSenior Vice President and Chief Financial Officerpdubuc@theratech.com438-315-6608
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT. Theratechnologies will also provide further information on the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Company’s supplemental Biologics License Application for the F8 formulation of tesamorelin. The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc, Senior Vice President and Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks. Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below. CONFERENCE CALL INFORMATIONConference Call DateFebruary 21, 2024Conference Call Time8:30 a.m. EDTWebcast linkhttps://edge.media-server.com/mmc/p/6fyph854Dial in1-888-317-6003 (toll free) or 1-412-317-6061 (international)Access Code0664356CONFERENCE CALL REPLAYToll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)International Toll1-412-317-0088Replay Access Code3842515Replay End DateFebruary 28, 2024To access the replay using an international dial-in number, please select this link:https://services.choruscall.com/ccforms/replay.html An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter). Contacts: Philippe DubucSenior Vice President and Chief Financial Officerpdubuc@theratech.com438-315-6608
